Aflibercept - Regeneron Pharmaceuticals/Bayer/Sanofi

Drug Profile

Aflibercept - Regeneron Pharmaceuticals/Bayer/Sanofi

Alternative Names: AVE-0005; BAY-865321; Eylea; Eylia; Vascular endothelial growth factor Trap; Vascular endothelial growth factor Trap-R1R2; VEGF Trap (R1R2); VEGF Trap-Eye; Zaltrap; Ziv-aflibercept

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Yakuhin; Centre Oscar Lambret; GERCOR; Greater Houston Retina Research; Guys Hospital; Hellenic Cooperative Oncology Group; Moorfields Eye Hospital; National Cancer Institute (USA); Regeneron Pharmaceuticals; Sanofi; sanofi-aventis; University of Ulm
  • Class Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Branch retinal vein occlusion; Central retinal vein occlusion; Choroidal neovascularisation; Colorectal cancer; Diabetic macular oedema; Diabetic retinopathy; Wet age-related macular degeneration
  • Phase III Glaucoma; Polypoidal choroidal vasculopathy
  • Phase II Central serous chorioretinopathy; Retinal disorders
  • No development reported Malignant ascites; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 13 Aug 2018 Regeneron anticipates a decision on its sBLA in Wet age-related macular degeneration from the US FDA, by October 2018
  • 13 Aug 2018 US FDA issues a complete response letter (CRL) to Regeneron with regards to its sBLA filed for Wet age-related macular degeneration
  • 02 Aug 2018 Regeneron Pharmaceuticals submits a supplemental Biologics License Application for aflibercept for Diabetic retinopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top